Paragraph IV Disputes

Join the conference that the “who’s who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice.

Since 2006, when we launched our inaugural conference, pharmaceutical patent practitioners from throughout the country and in some instances across the globe have attended this conference to confer with each other and assess the implications and imprimaturs of court cases, legislation, and industry behaviors which affect the patent endgame and the pursuit of related profits. They also come to hear from Judges — both from the federal judiciary, and U.S. P.T.O.’s PTAB —, the FTC, and the FDA.

Leaders from both brand and generic drug companies recognize that this event is the single forum which serves both sides of the industry and is second to none in offering both legal and economic “take aways” for every sphere of this costly, complex and evolving litigation. This is the only event on market which not only addresses the hot topics, but also puts them within the context of pre-suit considerations, case filings, final adjudication and every step in between. This unique dynamic exemplifies not only the importance of the content and legal theory presented, but the contending business acuities as well.

We invite you to join us at this flagship event to get caught up on legal developments and learn how your peers (and opponents) are navigating the ever-changing landscape – but don’t just take our word for it, hear from Michael Sitzman (DLA Piper), Huong T. Nguyen (Fosun Pharma USA Inc.), Evan Diamond (King & Spalding LLP), and Ryan M. Daniel (Fresenius Kabi USA, LLC) about why they value this event.